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Advances in nanotechnology have led to the development of novel ﬂuorescent probes called quantum dots. Quantum dots have
revolutionalized the processes of tagging molecules within research settings and are improving sentinel lymph node mapping and
identiﬁcation in vivo studies. As the unique physical and chemical properties of these ﬂuorescent probes are being unraveled,
new potential methods of early cancer detection, rapid spread and therapeutic management, that is, photodynamic therapy are
being explored. Encouraging results of optical and real time identiﬁcation of sentinel lymph nodes and lymph ﬂow using quantum
dots in vivo models are emerging. Quantum dots have also superseded many of the limitations of organic ﬂuorophores and are
a promising alternative as a research tool. In this review, we examine the promising clinical potential of quantum dots, their
hindrances for clinical use and the current progress in abrogating their inherent toxicity.
Copyright © 2007 Arthur M. Iga et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Quantum dots (QDs) are ﬂuorescent semiconductor nano-
crystals [1] with diameters of the order of 2–10 nanometers,
or roughly 200–10,000atoms [2]. QDs are made from a va-
riety of diﬀerent compounds. They are referred to as II–VI,
III–V, or IV semiconductor nanocrystals, based on the pe-
riodic table groups that these elements are from. Cadmium
selenide (CdSe) and Cadmium telluride (CdTe) nanocrystals
are examples of QDs which are group II–VI semiconductor
nanocrystal.CdSecontainscadmium(Cd)fromgroupIIand
selenide(Se)fromgroupVIoftheperiodictable.Theirnovel
optical and physical properties have attracted immense in-
terest in developing them for biological applications that re-
quire long-term, multitarget, and highly sensitive imaging.
The general structure of QDs comprises an inorganic core,
an inorganic shell, and an aqueous organic coating to which
biomolecules are conjugated, as shown in Figure 1. Modiﬁ-
cations in development can be used to control the size and
composition of the nanocrystal core to create speciﬁc spec-
tral properties of the QDs.
Developing high-quality QDs cores with a speciﬁc wave-
length, chemical composition, and size is a prerequisite. Syn-
thesis is achieved by heating appropriate organometallic pre-
cursors with stabilizers in high boiling solvents to produce
QDs, which can then be dissolved in nonpolar organic sol-
ventstoformtransparentcolloidalQDsdispersions.Organic
solvents such as trioctylphosphine oxide (TOPO) and hex-
adecylamine are commonly used and contain alkyl chains
which extend from the QDs surface, rendering the QDs ster-
ically stable as colloids [3]. Altering the size of the QDs core
during synthesis helps in tuning the color of emission [4].
The inherent toxicity of the individual ions (Cd2+,S e 2−,a n d
Te2−) within the cores has been circumvented by growing
an inorganic shell, that is, zinc sulphide (ZnS) on top of
the CdSe or CdTe nanoparticles [5]. The ZnS shell serves
as a barrier whereby the CdSe cannot come in contact with
the surrounding solvent and thus dissolve through ioniza-
tion. Secondly, it improves the quantum yield by passivat-
ing the surface nonradiative recombination sites. QDs have
been rendered water soluble [6] by providing a shell of func-
tionalized silica, phospholipids micelles [7], or linkers, such
as mercaptoacetic acid [5], dihydrolipoic acid [8], or am-
phiphilic polymers, that is, modiﬁed polyacrylic acid [9, 10].
In general, stabilization in aqueous solution is achieved by2 Journal of Biomedicine and Biotechnology
coating the QDs in amphiphilic polymers or by ligand ex-
change.
In order to use QDs in biological applications, QDs have
been integrated with biomolecules. QDs are modiﬁed with
bifunctional or amphiphilic molecules with one end bind-
ing or interacting with the QDs surface and the other po-
lar end protruding from the surface [11]. QDs are conju-
gated electrostatically either directly, between QDs and pro-
teins engineered to incorporate charged domains or via a
bridge. Covalent coupling has also been harnessed whereby
QDs bioconjugates are bound through carboxylic acids and
biomolecules.StabilizationofQDsinaqueoussolutions pro-
vides some QDs with coats which possess reactive functional
groups such as amines, carboxylic acids, alcohols, and thiols
[6, 8, 12]. Through these functional groups, covalent conju-
gation with a variety of biological molecules can be achieved.
Once a biological interface has been provided, QDs can ef-
fectively and speciﬁcally target diﬀerent biomakers at cellu-
lar, tissue, tumor, and organ levels. The above developmental
process has been summarized in Figure 2 and an overview
of the current techniques of QDs—conjugate synthesis, bio-
functionalization, and bioconjugation has been summarized
in Table 1.
2. CLINICAL POTENTIAL (IN VIVO APPLICATIONS)
The unique properties of QDs can be put to use in a wide va-
riety of biological applications. A key feature is that they can
be modiﬁed with a large number of molecules and linkers to
optimize their functionality for particular applications. QDs
have been used to selectively tag molecules, proteins, and
cells [8,9,13,14]ofinterest.QDshavegreatpotentialforuse
insentinellymphnode(SLN)mappingwhichisthemapping
of the ﬁrst tumor draining lymph node, [15–19], diagnos-
tic tools (e.g., imaging), for therapeutic purposes (e.g., drug
delivery and cancer treatment) [14], live cell labelling, and
tracking over long periods of time [20]. Multicolor in vivo
imaging has enabled noninvasive surgeries to be carried out
in a way that has not been feasible without QD.
3. GUIDING CANCER SURGERY
3.1. TypeIIQDs
When tissues absorb light, there is a possibility that ﬂuores-
cent light will be emitted. This causes tissue “autoﬂuores-
cence” which can severely limit signal to background ratio.
Some organs have increased green autoﬂuorescent, for ex-
ample, skin, small intestine, gall, and urinary bladder when
excited with blue light. Exciting the gall and urinary bladder
withgreenlightwillreducetheirautoﬂuorescence[21];how-
ever, the use of a near-infrared (NIR) light reduces ﬂuores-
cence background immensely. Type II QDs emit light within
the NIR spectrum and have been used for cancer-guided
surgery. Type I QDs structures are composed of CdSe/ZnS or
CdTe/ZnS (core/shell) structure whereas Type II QDs struc-
tures are composed of CdTe/CdSe (core/shell) or CdSe/ZnTe
(core/shell) heterostructures. Type II structures can allow ac-
Core, nanocrystal
(i.e., CdTe,CdSe)
Inorganic shell
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Conjugated biomolecules
(i.e., antibodies)
Figure 1: General structure of a QDs-modiﬁed from [21].
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Figure 2: Overall development of QDs for biological application.
cess to wavelengths that would otherwise not be available
with a single material [32].
3.2. Sentinellymphnodemapping
SLN identiﬁcation and lymphatic mapping are one of the
most revolutionary advances in surgical oncology in recent
years [33]. Mapping and removal of the SLN provides accu-
rate staging and therapeutic planning, determining the need
foradjuvantoncologicalmanagement[34].IntheUSA,lym-
phatic mapping and SLN biopsy have become the standard
of care for melanoma, with increasing acceptance in breast
cancer and a growing acceptance in tumors of the gastroin-
testinal tract [35]. Identiﬁcation of the sentinel node can
be performed by the use of a radioisotope and intraopera-
tive handheld gamma probe, a vital blue dye, or a combi-
nation of the two [34]. Current techniques of SLN mapping
are limited by unpredictable drainage patterns, high back-
ground signal, and the inability to image lymphatic tracers
relative to surgical anatomy in real time [15]. Novel ﬂuores-
cent probes (QDs) have been developed to provide real-time
image-guided localization using an NIR ﬂuorescence system
which facilitates the resection of the SLN [15–19].Arthur M. Iga et al. 3
Table 1: Overview of current techniques for synthesis, biofunctionalization, bioconjugation of QDs, and their conjugates.
First author Synthesis Biofunctionalization Bioconjugation Bioapplication
Zhou [22] ZnS capped
Amphiphilic polymer
shell, carboxylic acid,
and amine
functionalized
Peptide ligand Selective cell surface and
single-molecule imaging
Tortiglione [23] ZnS capped
Amphiphilic polymer
shell, diamino PEG
functionalization
Glutathione (GSH)
Biolabelling Hydra
vulgaris a freshwater
invertebrate
Selvan [24] Fe2O3-CdSe magnetic
QDs (noZnS capping)
Silicanization with
surface amine groups
Oleyl-O-poly(ethylene
glycol)succinyl-N-
hydroxysuccinimidyl
ester
Cell membrane targeting
for biolabelling and
imaging of live cells
Kampani [25] ZnS capped PEG layer Biotin-streptavidin
complex
Quantitative analysis of
viral binding and
attachment of human T
cell leukemia virus type I
Medintz [26] ZnS capped Hexahistidine peptide
linker with thiol DNA oligonucleotides Genetic analysis
Albuquerque de farias [27] CdS/Cd(OH)2(no ZnS
capping)
Glutaraldehyde
cross-linking
Anti-A monoclonal
antibody
Biolabelling of human
erythrocytes
Gao [28] ZnS capped
Mercaptoacetic acid with
bovine serum albumin
coating to increase
quantum yield and to
provide amine and thiol
functional groups
None Potential for molecular
sensing
Wolcott [6] Silica capped
PEG and
thiol-terminated
biolinkers
Immunoglobulin G
proteins Biolabelling and imaging
Tan [29] ZnS capped Chitosan
Human epidermal
growth factor receptor 2
antibody
Tracking of RNA
delivery
Parungo [19] CdSe inorganic shell Oligomeric phosphines None Pleural space SLN
mapping
Van Tilborg [30] ZnS shell Paramagnetic lipid Gd-
DTPA-bis(stearylamide)
Human annexin A5
protein molecules
Multimodal detection of
apoptotic cells
Jaiswal [8] Zns shell Dihydrolipoic acid
(DHLA)
Avidin or
antiP-glycoprotein
antibody
Long-term imaging of
live cells
Dubertret [7] ZnS capped Phospholipids Deoxyribonucleic acid
(DNA)
Labelling of Xenopus
embryos
Mulder [31] ZnS shell
Pegylated phospholipids
and a Paramagnetic lipid
Gd-DTPA-
bis(stearylamide)
Arginine-glycine-
aspartic acid (RGD)
peptides
In viro targeting of
human endothelial cells
Bharali [5] ZnS shell Mercaptoacetic acid Folic acid Imaging of live cells
Wu [9] ZnS shell Amphiphilic polymer Streptavidin or
anti-Her2 antibody
Labelling of cancer
marker Her2
Tumor staging and treatment planning is improved if as-
sessment of the primary lymph node draining a tumor site
is accurate. Gastrointestinal (esophageal, gastric, jejuna, and
colonic)andpulmonarySLNmapping havebeencarriedout
in in vivo models with a real-time NIR ﬂuorescence imaging
system. NIR ﬂuorescent QDs have been used for intraopera-
tivemappingoflymphaticdrainageofvariousorgansandfor
guiding excision of the primary draining node on a patient-
speciﬁc basis [15, 18].
3.3. GastrointestinalSLNmapping
In gastrointestinal SLN mapping, injection of 200pmol of
NIR ﬂuorescent QDs into various intra-abdominal organs4 Journal of Biomedicine and Biotechnology
Color video NIR ﬂuorescence Color-NIR merge
A
u
t
o
-
ﬂ
u
o
r
e
s
c
e
n
c
e
S
u
b
s
e
r
o
s
a
l
Q
D
i
n
j
e
c
t
i
o
n
5
s
p
o
s
t
-
i
n
j
e
c
t
i
o
n
1
m
i
n
p
o
s
t
-
i
n
j
e
c
t
i
o
n
(
z
o
o
m
e
d
)
3cm
3cm
3cm
2cm
(a)
Color video NIR ﬂuorescence Color-NIR merge
p
o
s
t
-
r
e
s
e
c
t
i
o
n
(
z
o
o
m
e
d
)
2cm
(b)
Figure 3: NIR ﬂuorescent SLN mapping of the porcine colon.
(a) NIR ﬂuorescent images of the surgical ﬁeld pre-, during, and
postinjection of NIR quantum dots. (b) Same image in “(a)” reveals
no QDs ﬂuorescence in the area of the excised SLN [15].
identiﬁed the SLN in less than 60 seconds and the aﬀerent
lymphatics in 100% of the cases [15]. QDs may be engi-
neered to precise sizes which enable localization in the SLN
unlike blue dye which contains particles <5nm that can pass
throughmultiple nodes thereforeleadingto false-positive re-
sults [15]. Examination of the operative site after surgery can
be done to ensure successful removal of the lymph nodes.
This has been demonstrated in Figure 3 where images after
SLN excision in a porcine colon reveal no ﬂuorescence in the
areaoftheexcisedSLN.However,SLNanalysisbythepathol-
ogist is facilitated as the QDs help identify the speciﬁc part of
the SLN that is most likely to contain malignant cells [16].
3.4. PulmonarySLNmapping
In pulmonary SLN mapping, injected QDs identiﬁed the
SLN within 1 minute, whereas isosulfan blue (the gold stan-
dardvisiblelymphatictracer)couldbevisualizedinthesame
node within 4minutes. In contrast to QDs, isosulfan blue re-
duces clarity due to extravasation. NIR QDs do not inter-
fere with the visualization of the surgical ﬁeld as they are
invisible to the human eye [18]. NIR ﬂuorescence imaging
with QDs in two species demonstrated that the highest su-
perior mediastinal lymph nodes are the SLNs of the pleural
space [19]. Advancement of the NIR ﬂuorescence imaging
with QDs indicate a promising future in clinical lymphatic
mapping. Table 2 shows various studies using NIR ﬂuores-
cent QDs in SLN mapping.
4. CANCER IMAGING
4.1. Strongpotentialforsensitivityincancerdiagnosis
QDs have been shown to speciﬁcally and eﬀectively label
molecular targets at cellular level and they have been used
as a diagnostic tool for cancer in in vivo studies [14, 36].
In vivo targeting studies of human prostate cancer devel-
oped in nude mice showed that QDs probes accumulated
in tumors by both the enhanced permeability and reten-
tion at tumor sites through antibodies binding to cancer-
speciﬁc cell surfacebiomarkers [14]. For active tumor target-
ing,antibody-conjugatedQDswereusedtotargetaprostate-
speciﬁc membrane antigen (PSMA). Previous research has
identiﬁed PSMA as a cell surface maker for both prostate ep-
ithelial cells and neovascular endothelial cells [37]. Results
obtained from QD-PSMA antibody probes injected into the
tail vein of a tumor-bearing mouse showed that nanoparti-
cles were delivered and retained by the tumor xenograft [14].
Comparison with other surface modiﬁcations of the QDs
probe: carboxylic (COOH) group, polyethylene glycol (PEG)
groups,andPEGplusPSMAantibodyshowed,notumorsig-
nals were detected with the COOH probe, only weak tumor
signals were observed with the PEG probe (passive targeting)
and intense signals were detected in PEG-PSMA antibody-
conjugated probe [14]. The above results presentnew oppor-
tunities for ultrasensitive imaging of biomarkers involved in
cancer invasion and metastases, as a result alerting clinician
to early intervention.
Using QDs, precancerous biomarkers have been investi-
gated in cervical cancers [13]. It is widely accepted among
immunohistochemistry studies in the cervix that epidermal
growth factor receptor (EGFR) levels demonstrate a statis-
tically signiﬁcant increase when a lesion progresses from a
dysplastictoaninvasivelesion[38].SiHacervicalcancercells
were targeted with QDs conjugated to anti-EGFR antibodies
[13]. This showed speciﬁc labelling of EGF receptors. Using
optical imaging technologies, they postulated that QDs can
help visualize changes in the cervical cancer at the molec-
ular level hence the need for early intervention. The ability
to image molecular changes will directly aﬀect patient care
by allowing earlier detection of disease and identiﬁcation of
speciﬁc molecular targets for treatment [39].
5. THERAPEUTIC
5.1. Photodynamictherapyincancertreatment
Photodynamic therapy (PDT) has been developed as a novel
management technique for a diverse variety of cancers [40].
In conjunction with surgical treatment, PDT has been used
successfully in lung cancer and is increasingly being used on
gastrointestinal malignancies. This modality is already an es-
tablished treatment entity in ophthalmology. During PDT,Arthur M. Iga et al. 5
Table 2: Studies using NIR ﬂuorescent QDs (Type II NIR QDs) in SLN mapping, using emission of 840–860nm wavelength [15–19].
NIR ﬂuorescent
Lymph tracer
Model Tissues/organs Outcome
Soltesz [15] Pig GI tract (gastric,
jejunal, colonic)
IdentiﬁedSLNinlessthan1
minute in 100% of pigs
Soltesz [18] Pig Lungs
Identiﬁed SLN within 5 minutes in
100% of pigs
Parungo [19] Rat and pig Pleural space
Demonstratedthatstation1lymph
nodes are the SLN of the pleural
space in rats and pigs
Kim [16] Mouse and pig
Limbs (lymphatic
ﬂow to axilla and
groin)
IdentiﬁedSLNin3–4minutes
(percentage not mentioned)
Parungo [17] Pig Esophagus A single SLN was identiﬁed within
5 minutes in 100% of pigs
singlet oxygen is generated in the diseased cells by a sim-
ple and controllable light-activated process. This process in-
volves a photosensitizer that is capable of absorbing light of
an appropriate wavelength and utilizing that energy to excite
oxygen to its singlet state which initiates apoptosis of can-
cer cells [41]. Selectivity is signiﬁcant in cancer treatment
and has been utilized in PDT. Only cells which are simulta-
neously in contact with the photosensitizer, light and in the
presence of oxygen are subjected to the cytotoxic reactions
[42]. In the work of Samia et al. [43], CdSe QDs were linked
to a silicon phthalocyanine (Pc4) photosensitizer through an
alkyl group, and used as a primary energy donor. Excitation
of CdSe QDs activated emission of Pc4 photosensitizer at
680nm, which enabled the use of an excitation wavelength
that is not absorbed by the sensitizer. Through the ﬂuores-
cence resonance energy transfer mechanism from QDs to the
silicon Pc4 photosensitizer, oxygen reactive species were gen-
erated for photodynamic cancer therapy. Furthermore, the
semiconductor nanocrystals alone were found to generate
oxygen reactive species without a mediating photosensitizer.
In view of their ﬂexible spectral characteristics, QDs can be
engineered in size and composition to match those of any
PDT photosensitizer and be used as energy donors. Figure 4
shows a summarized mechanism of PDT involving QDs.
5.2. Drugdelivery
QDsprobeshavebeenshowntoaccumulateintumorsbyen-
hanced permeability and retention at tumor sites or by anti-
body binding to cancer-speciﬁc cell surface biomarkers [14].
Enhanced permeability and retention (EPR) eﬀect is the ba-
sis for selective targeting of macromolecular drugs to tumors
and the concept is now utilized for selective delivery of many
macromolecularanticanceragents[44].Styrene-maleicacid-
doxorubicin micelles utilizing EPR eﬀect have been shown to
enhance the therapeutic eﬀects of doxorubicin while reduc-
ing toxicity [45]. Polyethylene glycol-liposomes encapsulat-
ing doxorubicin were less extensively taken up by the retic-
uloendothelial system and were able to extravasate through
Light
Quantum dot
Cancer
cell
ROS
Photosensitizer
Activated photosensitizer
Apoptosis
Oxygen molecule
Figure 4: Summarized mechanism of PDT involving QDS [43].
“leaky” tumor vasculature resulting into doxorubicin local-
ization in tumor tissue [46]. EPR can deliver therapeutic
agents to desired targets while reducing systemic toxicity. Re-
search in drug delivery has beneﬁted from the use of nan-
otechnology in dendrimers [47] and liposomes [48]. Com-
bining QDs, speciﬁcally their ability to bind molecules that
recognize cancer cells and a drug, might oﬀer a new strategy
for molecular cancer therapy through targeted molecular de-
livery vehicles.6 Journal of Biomedicine and Biotechnology
6. QDs AS A RESEARCH TOOL
6.1. Bio-sensitive
The rate of success of QDs usage in the laboratory has in-
creased immensely. As a biosensitive tool, detection of sin-
gle bacteria pathogenic Escherichia coli 0157:H7 serotype
was made possible with the use of QDs [49]. Under con-
tinuous excitation, QDs retained their high ﬂuorescence in-
tensities for hours while organic dyes bleached in seconds,
allowing more rapid and accurate identiﬁcation of E. coli
0157:H7 in single-cell ﬂuorescence-based assays. QDs al-
lowed lower limits of detection, which increased sensitiv-
ity, and has important implications in the development of
any ﬂuorescent immunoassay for bacteria pathogens. QDs-
labeled chromatophores have been used as virus detectors to
detect H9 avian inﬂuenza virus based on antibody-antigen
reaction [50]. Selective determination of free cyanide in wa-
ter with high sensitivity (detection limit of 1.1×10
−6 M) has
beendemonstratedviaanalyte-inducedchangesinQDspho-
toluminescence after photoactivation [51].
6.2. Bioimaging
QDs have been used to stain Hydra vulgaris (a fresh water in-
vertebrate) and study its behavior [23], to image in in vivo
tumor vasculature in mice [39], and to study vasculogen-
esis in Zebraﬁsh [52]. Bovine serum albumin-coated QDs
have been used as a ﬂuorescent, angiographic contrast agent
in the NIR range [39]. Observation of vessels surrounding
andpenetratingamurinesquamouscellcarcinomainaC3H
mouse was made possible. Distinction between the superﬁ-
cial vessels associated with the tumor and deep vessels could
be made with the deep vessels visible in ﬂuorescence images.
Colabelling of Zebra ﬁsh embryo’s blood vessels with QDs
enabled documentation of the embryonic pattern of vascu-
logenesis as the QDs marked the newly formed vessels [52].
As a result, detailed knowledge about the progression of vas-
cular systems development has been obtained.
6.3. Biolabelling
Diﬀerent groups have successfully demonstrated that QDs
can be tagged and incorporated into cells and drugs without
aﬀecting their activation and function [20, 27, 53–55]. Up
to 108 QDs could be injected in Zebra ﬁsh embryos without
malformations or developmental problems during embryo-
genesis [52]. QDs were used to follow labeled cells during
their developmental stages to reveal cellular behavior. Semi-
conductornanocrystalshavebeenusedforinvivotrackingof
cancer cells during metastases. Tumor cells labeled with QDs
were used in ﬂuorescence microscopy to study extravasation,
a part of metastasis formation at high resolution in living an-
imals [20]. QDs-labeled cells survived the selective pressure
ofthecirculationandmanagedtoextravasateintotissuesjust
as eﬀectively as unlabeled cells. The use of QDs provided the
opportunity to simultaneously identify and study the inter-
actions of multiple diﬀerent populations of tumor cells and
tissue cells in a natural tissue environment.
7. COMPARISON TO OTHER
FLUORESCENT COMPOUNDS
Fluorescent QDs that overcome many of the limitations of
organic ﬂuorophores are a promising alternative. Organic
ﬂuorophores’s excitation and emission wavelengths are de-
pendent on a chemical structure whose tuning to a pre-
cise wavelength requires complicated chemistry. The quan-
tumyieldofconventionalorganicﬂuorophoresisusuallyless
than 15% in aqueous environments [21]. QDs have a large
absorption cross-section, good quantum yield, and a large
saturationintensitythatmakesthemmuchbrighterthanﬂu-
orescence dyes or ﬂuorescent proteins [56]. QDs have broad-
band absorbance to the blue of emission which has been ex-
ploited for in vivo applications. Studies have demonstrated
that tissue scatter and absorbance may sometimes oﬀset in-
creasing QDs absorption at blue light wavelength and coun-
teract this advantage [57]. However, QDs that emit in the
NIR region of the electromagnetic spectrum have been de-
veloped for live tissue imaging. Within the NIR of the spec-
trum there is low tissue scattering and absorption, yielding
great tissue penetration depth and optical signal [11].
In the work of Gao et al. [14], sensitivity detection and
spectral features of QDs and green ﬂuorescent protein (GFP)
were compared by linking translocation peptide HIV Tat to
QDsanddeliveringthemintolivingcancercells.QDs-tagged
cells and the GFP-transfected cells were similarly bright in
cell cultures, however only the QDs signal was observed in
vivo. GFP signals were not discerned at the injection site.
Even if results did not provide an absolute intensity compar-
ison between GFP and QD, they provided a qualitative spec-
tral comparison demonstrating that the emission spectra of
QDs could be shifted away from the autoﬂuorescence, allow-
ing spectroscopic detection at low signal intensities [14]. The
large Stroke’s shift which is the diﬀerence between the peak
absorption and the peak emission wavelengths enables ﬂu-
orescent signals from QDs to be easily separated from scat-
tered excited light [13].
QDs are more highly photostable than organic ﬂuo-
rophores. Organic dyes are often photobleached and fade by
>90% in less than one minute, whereas QDs are stable for
more than 30minutes under identical experimental condi-
tions [58]. In vivo ﬂuorescence quenching of QDs-micelles
and rhodamine green-dextran was compared after 80 min-
utes of constant illumination at 450nm under the micro-
scope. The QDs ﬂuorescence intensity remained the same,
whereas the dextran had photobleached [7]. While detecting
tumor marker CA125 in ovarian carcinoma, Wang et al. [59]
compared the photostability of QDs signals and a conven-
tional organic dye ﬂuorescein isothiocyanate (FITC). QDs
signals were found to be more speciﬁc and brighter than
those of FITC, with exceptional photostability during con-
tinuous illumination for 1hour, whereas FITC signals faded
very quickly and became undetectable after 24minutes of
illumination. Arguably, the extreme photostability of QDs
may have little signiﬁcance in the context of clinical potential
as ﬂuence rates that photobleach organic ﬂuorophores have
no place in the clinical settings. The susceptibility of con-
ventional ﬂuorophores to photobleacing limits the ﬂuenceArthur M. Iga et al. 7
rate that can be applied to a sample and as a result it af-
fects the sensitivity of detection [21]. In order to minimize
the potential for toxicity, Kim et al. [16] increased the ﬂu-
ence rate, and proportionally decreased the dose of injected
QDs.Theirphotobleachingdatasuggestedthatatleasta100-
fold lower dose could be used. Although QDs are photo-
stable and they can achieve high-quantum yields in organic
solvents, they underperform organic ﬂuorophores as a func-
tion of molecular volume. That is, given their size, QDs are
much poorer photoluminescence agents than organic ﬂuo-
rophores. In depth, discussions of various properties of QDs
inrelationtoconventionalﬂuorophoreshavebeenpublished
[14, 21, 56, 60].
8. RECENT DEVELOPMENTS
In the burgeoning ﬁeld of nanotechnology QDs synthesis,
biofunctinalization and bioconjugation techniques are ad-
vancing rapidly. Conventionally inorganic cores have been
capped with inorganic shells, ZnS; while other techniques
of capping the core with cadmium sulphide (CdS), Sil-
icon, CdTe or CdSe to form CdTe/CdSe (core/shell), or
CdSe/ZnTe(core/shell)[32,36,61]areemerging.CdTe/CdSe
(core/shell) or CdSe/ZnTe (core/shell) is expected to have
many novel properties that are fundamentally diﬀerent from
CdSe/ZnS (core/shell) or CdTe/ZnS (core/shell) because of
their valence and conduction band diﬀerences [32]. These
properties are being exploited in in vivo applications. Water-
based synthesis of highly luminescent QDs is a promising
alternative to QDs prepared in organic solvents [62–65]i n
cellular imaging and biolabelling. It oﬀers the advantage of
engineering water soluble, stable QDs with smaller hydrody-
namic diameters that are easily conjugated to biomolecules.
Synthesis of group III–V semiconductor QDs (i.e., InP) as
a luminescence probe for imaging in live cells has been re-
ported [5]. Group III–V QDs are potentially less toxic as op-
posed to II–VI QDs theoretically making them better probes
for bioapplications. Drawbacks to utilizing III–V QDs as ﬂu-
orescent probes are their low quantum yield and laborious
synthesis. Future work to harness their full potential will
include increasing the quantum yield and minimizing the
aqueous size of the quantum dot.
The aqueous size of the QDs should be appropriately
matched to the in vivo study of interest [16]. Types 11 QDs
with aqueous sizes of 15.8–18.8nm have been used for SLN
mapping[15–19].RecentworkofZimmeretal.[66]demon-
strates the synthesis of a size series of (InAs)ZnSe (core) shell
QDs that emit in the NIR and exhibit aqueous size of less
than 10nm. These QDs circulated in the blood before they
were able to migrate out of the blood vessels and into the
interstitial ﬂuid. It is a signiﬁcant achievement in the devel-
opment of QD; hence after intravenous injection, they can
possibly penetrate most normal organs or micrometastases.
Bimodal nanoparticles consisting of QDs that are en-
capsulated in a paramagnetic micelle to enable both optical
imaging and magnetic resonance imaging (MRI) are being
developed [30, 31]. This has potential to detect pathologi-
cal processes in in vivo models and tumor angiogenesis with
both intravital ﬂuorescence microscopy and MRI [30, 31].
Various strategies of biofunctionalization and bioconjuga-
tion have been developed to generate water-soluble QDs as
previously discussed however some have encountered prob-
lems. QDs solubilization with mercaptoacetic acid [5, 28]
have been reported to cause a drop in ﬂuorescence quan-
tum yields after solubilization and desorption of mercap-
toacetic acid has led to aggregation and precipitation of sol-
ubilized QDs [28]. Bovine serum albumin has been used to
improve the ﬂuorescent intensity of the QDs solubilized in
mercaptoaceticacid[28].Techniquesofbiofunctionalization
and bioconjugation have to (i) be reproducible, (ii) maintain
the size of the QDs complex to a minimum, (iii) maintain
the photoluminescence properties of the QDs, (iv) provide
chemical stability of the QDs complex, and (v) be reliable
methods for conjugation to biomolecules.
9. DISCUSSION
The future of QDs is promising however there are funda-
mental questions that still need to be answered. Questions
have arisen about their toxicity, long-term in vivo stability
and metabolic elimination from the body. Prevention of core
atoms, Cd atoms, from being accessible to or potentially re-
leased in the surrounding environment has been passivated
by shelling the core in extra layers of material. Questions re-
garding biochemical mechanisms of cytotoxicity are slowly
beginning to be answered, mechanisms suggested involve
production of reactive oxygen species such as free hydroxyl
radicals and singlet oxygen [43, 67, 68]. Treatment with N-
acetylcysteine (NAC), an antioxidant, has shown to prevent
“naked”QD-inducedorganelleandcelldamagewhichisme-
diated by reactive oxygen species (ROS) [68]. In the work of
Lovri´ c et al. [68], NAC improved cell survival by reducing
concentration of ROS in cell culture medium. NAC further
induced the synthesis of glutathione, an eﬀective cellular an-
tioxidant, and possibly improved QDs surface passivation,
leading to less damage to the mitochondrial redox system.
Understanding the mechanisms of QDs cytotoxicity is sig-
niﬁcant in order to make use of their potential.
Studies of bovine serum albumin-QDs conjugates have
shown bovine serum albumin to provide protection against
QDs-induced cytotoxicity [69]. Albumin reduced or elimi-
nated toxicity through possession of peptides responsible for
the extracellular antioxidant defense system. However, work
on mercarpto-undecanoic acid QDs (MUA-QDs) in sheep
serum albumin (SSA); showed that MUA-QDs caused cell
damage even at low concentrations [70]. Cytotoxicity caused
by mercapto-undecanoic acid QDs in sheep serum albumin
was attributed to the nonchemical bonds between the SSA
and the MUA-QDs. There could be a possibility that MUA
QDs capping alone without the QDs caused cell damage as
eﬀects of MUA alone on vero, hela cells and primary hu-
man hepatocytes were not assessed. There is a need to evalu-
ate the strength of bonds between the QDs and their surface
coatings. Possible enzymatic, physicaland chemical degrada-
tion of the semiconductor cores upon injection in live an-
imals could occur. Under what shear stress in vivo circu-
latory pressures are the surface coatings likely to hold? Ar-
guably, QDs do not have to be in the circulatory system for8 Journal of Biomedicine and Biotechnology
clinical application, however, they may gain access to circu-
lation through blood and lymphatic channels therefore their
degradation needs to be assessed.
Polydentate phosphine-coated NIR QDs were found to
be stable in 100% serum after incubation for twice the
amountoftimeneededforatypicalSLNmappingprocedure
[16]. There was minimal disruption in the optical properties
of the NIR QDs, which is promising for biological applica-
tions. Biocompatible polymer such as silicon are safer mate-
rials to use for encapsulation and are highly unlikely to de-
grade [14, 70].
QDs surfaces can control serum lifetime and pattern of
deposition [10] which has been exploited in many in vivo
applications. Deposition in the reticuloendothelial system is
signiﬁcant for detecting SLNs. Polymer encapsulation with
surface PEG groups reduced the rate of organ uptake and
improved circulation half-life of QDs, leading to accumula-
tion of the nanoparticles in the tumor [10]. The size of the
nanoparticles plays a vital role in avoiding ﬁltration by the
reticuloendothelial system. In a similar strategy exploited in
drug delivery systems, drug-carrying liposomes are believed
to have an increased lifespan partly due to their ability to ex-
travasate through the splenic and liver fenestrae [71].
Diﬀerent reports have been published highlighting the
inertness of QDs in vivo studies where physiological func-
tion has not been aﬀected, however lots of gaps exist re-
gardingbiodegradationandexcretion.EncapsulationofQDs
prepared in organic solvents is one of the most widely used
methods of abrogating QDs toxicity, however new ways of
QDs synthesis and negating QDs toxicity need to be devised.
Adding extra coating onto the QDs core improves blood
halﬂife which in essence increases the dissolution. Additional
QDs surfaces will not enhance the translation of QDs to the
clinical setting as they do not eliminate the toxic cores. Sur-
face coatings and surface modiﬁcation prior to in vivo ap-
plication may have a big role to play on QDs degradation
or elimination. However, the current state and design of the
QDs precludes the elimination of QDs from the body. The
ability to functionalize QDs with many diﬀerent chemical
groups increases its aqueous size. This presents an enormous
predicamentsincethecore,shell,organiccoatings,andfunc-
tional groups will be larger than the pore size of the endothe-
lium and the renal threshold. To the best of our knowledge
there are no in vivo studies on the metabolism and excretion
of QD.
The engineering of QDs for biological applications is at
its infancy. Progress is being made in designing sizable and
biocompatible QDs. As optimism in exploiting QDs clinical
potential is high, there is need to assess their cytotoxicity, in
vivo distribution, and excretion. A much more work needs
to be done to combat QDs inherent toxicity before they are
applied in the clinical settings.
In summary, the development of QDs for clinical usage
will have to circumvent a few more hurdles to gain recogni-
tion as a novel ﬂuorescent probe for SLN, early cancer de-
tection, rapid spread, and therapeutic intervention. The idea
of engineering QDs for clinical purposes is not far fetched.
The ideal QDs for clinical application would possess non-
toxic elements, being chemically stable and with tunable size
to perfectly negate through the endothelial pores, and would
need to be completely eliminated from the body. With im-
provements in nanotechnology, nanotoxicology, and chem-
istry, some of the above goals could be achieved; however, it
will be diﬃcult to replace the toxic core of the QDs without
losingtheopticalproperties,oroureﬀortshavetoberedirect
to less-toxic elements.
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